Moyle G, Meng F, Wan H, Sklar P, et al. Resolution of Neuropsychiatric Adverse Events After Switching to a Doravirine-Based Regimen in the Open-Label Extensions of the DRIVE-AHEAD and DRIVE-FORWARD Trials. J Acquir Immune Defic Syndr 2025 Jan 3. doi: 10.1097/QAI.0000000000003599.
PMID: 39748155